drugset / Trial / NCT03520543

[11C]Yohimbine PET Study of alpha2-AR

NCT03520543

Phase 1 Completed 16 enrolled Hospices Civils de Lyon
RandomizedParallel-groupOpen-labelBasic science

Summary

The main purpose of this study is to model tissue specific kinetics of \[11C\]Yohimbine in healthy male participants by positron emission tomography (PET) and the appropriate arterial input function (part A) ; to determine the reproducibility of measures (classical test-retest study, part B1) and to measure the blocking of \[11C\]Yohimbine uptake in the brain following single oral dose administration of clonidine (part B2).

Timeline

Start
2018-05-21
Primary completion
2018-07-21
Completion
2019-01-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Clonidine Other / unclassified 0.15 mg Oral
Subject [11C]Yohimbine Unknown 370 mbq Intravenous

Indications

No indication recorded.